Panbela Therapeutics Q1 2024 Earnings Report $0.32 -0.01 (-1.52%) (As of 12/20/2024 05:32 PM ET) Earnings HistoryForecast Panbela Therapeutics EPS ResultsActual EPS-$2.28Consensus EPS -$1.23Beat/MissMissed by -$1.05One Year Ago EPSN/APanbela Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APanbela Therapeutics Announcement DetailsQuarterQ1 2024Date5/15/2024TimeN/AConference Call ResourcesPBLA Earnings History 2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Panbela Therapeutics Earnings HeadlinesPanbela Therapeutics (NASDAQ:PBLA) Shares Down 7.6% - Here's WhyDecember 13, 2024 | americanbankingnews.comPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years. December 22, 2024 | Stansberry Research (Ad)Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comSee More Panbela Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Panbela Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Panbela Therapeutics and other key companies, straight to your email. Email Address About Panbela TherapeuticsPanbela Therapeutics (NASDAQ:PBLA), a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.View Panbela Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
